Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy diversity 4-23 (IGHD4-23) is a gene segment in the immunoglobulin heavy locus (IGH) encoding a portion of the antibody heavy chain variable region. It is classified as a diversity (D) gene segment, participating in V(D)J recombination, the process that generates diversity in the antigen-binding site of immunoglobulin molecules. IGHD4-23 is denoted as "non-functional" in the current Ensembl annotation and functions as a genetic component, not as a protein or therapeutic target. Diversity segments combine with variable (V) and joining (J) gene segments to form the variable region of immunoglobulins, shaping the specificity and diversity of the adaptive immune response[2][1][4]. IGHD genes like IGHD4-23 do not represent receptors or functional molecular targets themselves, but rather are essential DNA elements used during B cell development to generate antibody diversity. IGHD4-23 is not a protein, receptor, or drug target; it is a short DNA gene segment used in the assembly of immunoglobulin genes through recombination[2][1]. The gene is annotated as "non-functional" in the human genome (ENSEMBL: ENSG00000227196)[2]. The primary role is in immunogenetic diversity generation; not directly implicated as a biomarker, therapeutic target, or disease gene. There are no drugs or mechanisms of action targeting IGHD4-23, as it does not produce a functional protein on its own. The IGHD4-23 symbol and name are correct, but it is often misinterpreted as a true functional target or receptor, which is not the case.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy diversity 4-23 (IGHD4-23).